News

Filter

Current filters:

PharmaMar

PharmaMar and Chugai link up to commercialize Aplidin in Europe

17-07-2014

Spanish drugmaker Zeltia, through its biotech subsidiary PharmaMar, and Japan’s Chugai Pharmaceutical…

AplidinBiotechnologyChugai PharmaceuticalEuropeLicensingOncologyPharmaMarplitidepsinZeltia

Spanish pharma companies plan to continue extending their footprint around the world

03-06-2014

Spanish pharmaceutical companies have developed a strong strategy in the last years to expand their products…

AlmirallCinfaEsteve GroupFerrer InternacionalGlobalGrifolsKern PharmaMarkets & MarketingPharmaceuticalPharmaMarSpain

Zeltia's Yondelis approved for sale in 10 new countries

04-12-2012

Pharma Mar, a subsidiary of Spain's Grupo Zeltia (ZEL: MC), says it has been advised by its licensee…

GlobalJanssenJohnson & JohnsonOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis

27-04-2011

There was mixed news this morning from the UK’s drug rationing body the National Institute for Health…

AmgenBiotechnologyCardio-vascularEuropeNplateOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

UK’s NICE turns down Zeltia’s Yondelis on lack of evidence for ovarian cancer drug

14-03-2011

Following a negative opinion last year, and despite the company offering a funding deal, the UK drugs…

EuropeOncologyPharmaceuticalPharmaMarPricingRegulationYondelisZeltia

Spain’s Zeltia posts 74% rise in EBITDA, with Yondelis sales up 65% in 2010

28-02-2011

Spanish drugmaker Grupo Zeltia reported net revenues 153.5 million euros ($211.4 million) in 2010 up…

FinancialPharmaceuticalPharmaMarYondelisZeltia

UK’s NICE turns down PharmaMar’s Yondelis and GlaxoSmithKline’s Arzerra

20-09-2010

The UK’s National Institute for Health and Clinical Excellence (NICE) gave another couple of negative…

ArzerraEuropeGlaxoSmithKlineOncologyPharmaceuticalPharmaMarPricingRegulationYondelisZeltia

Back to top